Drug intelligence / Profile preview

SAR439794

Development stage: Phase 1
Lead developer: Sanofi
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Sublingual

Overview

**SAR439794** is an investigational, sublingually administered peanut-allergen immunotherapy developed by Sanofi for peanut allergy. It consists of peanut extract sublingual immunotherapy adjuvanted with glucopyranosyl lipid A, a synthetic Toll-like receptor 4 agonist intended to modulate allergen-specific immune responses. In the completed Phase 1 TDR14287 study, SAR439794 was administered once daily using a fixed glucopyranosyl lipid A dose with an escalating peanut-extract dose; the program was discontinued following a strategic portfolio decision. ([sanofi.com](https://www.sanofi.com/assets/dotcom/content-app/clinical-studies/pharma/LETTER-T/TDR14287-results-summary.pdf0))

Other names: peanut extract sublingual immunotherapy adjuvanted with glucopyranosyl lipid A

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on SAR439794.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR439794.

Explore the full profile